Recent findings published in Emjreviews indicate that tirzepatide is associated with a 32% lower risk of major adverse cardiovascular events compared to alternative treatments. Tirzepatide functions as a dual incretin agonist of glucose-dependent insulinotropic peptide and glucagon-like peptide 1 receptors.
Tirzepatide Linked to Lower Risk of Major Cardiovascular Events
According to research covering 52,971 adults in the United States diagnosed with both Type 2 diabetes and established atherosclerotic cardiovascular disease, 17,618 individuals were treated with a sitagliptin placebo proxy while 35,353 initiated tirzepatide. After a one-year period, 2.9% of participants taking tirzepatide experienced a major cardiovascular event, compared to 4.4% of those taking sitagliptin. This equated to one additional major cardiovascular event prevented for every 70 people treated with tirzepatide instead of sitagliptin.
Individual Cardiovascular Outcomes and Infections
When analyzing specific cardiovascular incidents, researchers noted that tirzepatide was linked to a lower risk of heart attack, though there was no clear difference observed in the risk of ischaemic stroke between the two treatment groups.
Beyond cardiovascular endpoints, tirzepatide use was associated with fewer infections requiring hospital treatment. Data showed that for every 48 people treated with tirzepatide instead of sitagliptin, one hospitalisation for infection was prevented. Furthermore, researchers recorded fewer deaths caused by infection as well as fewer overall deaths among individuals taking tirzepatide. To verify these results, investigators evaluated unrelated health conditions and found no meaningful link between tirzepatide and those conditions.
Real-World Data and Comparative Analyses
As reported by News Medical, administrative claims databases in the United States were analyzed from May 2022 to May 2025 to emulate the SURPASS-CVOT trial design. The study evaluated patients aged 40 years and older with atherosclerotic cardiovascular disease and type 2 diabetes who had a body mass index of 25 kg/m2 or greater.
Additional clinical evaluations, including research presented during the American College of Cardiology’s annual meeting and published in Clevelandclinic, compared tirzepatide directly against dulaglutide. Steven Nissen, M.D., Chief Academic Officer of the Heart, Vascular & Thoracic Institute at Cleveland Clinic, noted that when assessing six major complications—including heart attack, stroke, coronary procedures, heart failure, kidney failure, and all causes of death—these events occurred in 23.7% of patients taking tirzepatide compared to 27.4% of those taking dulaglutide, representing a 16% lower risk for tirzepatide.
Risks of Treatment Interruption
While continuous medication provides sustained protection, studies emphasize the critical nature of maintaining therapy. Research from Washu highlights that stopping or interrupting GLP-1 treatments, such as tirzepatide and semaglutide, can quickly erase cardiovascular benefits.
Investigators following U.S. veterans with type 2 diabetes found that interrupting treatment for even six months led to an increase in cardiovascular risk, while gaps extending up to two years resulted in up to a 22% increase in the risk of heart attack, stroke, and death. Ziyad Al-Aly, MD, senior author and clinical epidemiologist, noted that discontinuation causes a resurgence in inflammation, blood pressure, and cholesterol, underscoring that continuous treatment is vital for sustained heart protection.
Keep reading